Trial Profile
Phase 3 trial of Obeticholic acid in NASH patients with cirrhosis.
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 May 2017
Price :
$35
*
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Fibrosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 10 May 2017 New trial record
- 04 May 2017 According to an Intercept Pharmaceuticals media release, company plans to initiate this trial during 2H 2017.